Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2485 articles with Johnson & Johnson Family of Companies
-
Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue reading.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Although vaccines and effective therapeutics are powerful tools in preventing and treating COVID-19, we’re not done battling the disease just yet. For those stories and more, read on.
-
DePuy Synthes Launches the UNIUM™ System as a Next Generation Power Tools System for Trauma and Small Bone Procedures
11/22/2021
DePuy Synthes, The Orthopaedics Company of Johnson & Johnson*, has launched the UNIUM™ System as the newest addition to its Power Tools portfolio.
-
The recommendation comes after a thorough evaluation of both products' effectiveness and safety profiles, presented at the Advisory Committee on Immunization Practices last week.
-
A week after announcing its intention to spin off its consumer health division, J&J revealed ambitious plans for its pharmaceutical business.
-
The U.S. Food and Drug Administration approved COVID-19 vaccine booster shots for all Americans ages 18 and over Friday morning.
-
Race is Heating Up for the First RSV Vaccine
11/17/2021
The market is expected to be worth $4.2 billion by 2027, with a CAGR of 14.9% between 2021 and 2027. -
Between the numerous COVID-19 vaccines and several new antiviral drugs, it would appear that the tools to end the COVID-19 pandemic are within reach. Here’s a look at some of the top stories.
-
Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business
11/12/2021
Johnson & Johnson announced its intent to separate the Company's Consumer Health business, creating a new publicly traded company.
-
The total revenue for the quarter was $9.74 billion, a leap of 47%. The COVID-19 vaccine, Vaxzevria, only contributed 1% to the company’s profit.
-
Johnson & Johnson is planning to break off its consumer products business from its pharmaceutical and medical device businesses. They will become two publicly traded companies.
-
Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World's Most Vulnerable People through Novel Humanitarian Buffer
11/10/2021
Johnson & Johnson has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance, to enable access to its single-shot COVID-19 vaccine through a novel mechanism – the COVAX Humanitarian Buffer – that will serve to protect the world's most vulnerable people.
-
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
-
The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.
-
The U.S. government canceled a contract with Maryland-based Emergent BioSolutions, which earlier in the year ruined about 15 million doses of the Johnson & Johnson COVID-19 vaccine.
-
Vaccinations will be required by January 4 under the new White House plan.
-
Both Moderna and Pfizer reported third-quarter financials this week, and it was instantly obvious that the COVID-19 vaccines are huge profit drivers for the companies.
-
In the face of Delta, the actual efficacy of the vaccines has come into question, while global cases and deaths from COVID-19 increased for the first time in two months, primarily in Europe.
-
Emergent BioSolutions, the manufacturer responsible for the doses in question, is reportedly just waiting for the U.S. FDA's signal to start shipping the vaccines.